Literature DB >> 6454019

Pharmacodynamic and metabolism studies on a new coronary vasodilator, N-(2-hydroxyethyl) nicotinamide nitrate (SG-75).

K Sakai, Y Ohba, M Akima, H Kamiyama, Y Hinohara, H Nakano.   

Abstract

Pharmacodynamics and metabolism of N-(2-hydroxyethyl) nicotinamide nitrate (SG-75) were investigated in rats in relation to its main metabolic product. When SG-75 was orally administered, SG-75 and SG-86, a denitrate compound of SG-75, appeared in the blood. Within 7 yr, approximately 60% of the administered SG-75 were recovered in the urine as SG-86. When administered intraduodenally, SG-75 was rapidly absorbed and transferred in an unaltered form into the portal vein. SG-75 possessed hypotensive and coronary vasodilating actions, while SG-86 had little effect on the cardiovascular system. The coronary vasodilating effects of SG-75 k(0.3-20 micrograms i.a.) were unaffected by the continuous infusion of SG-86 into the coronary perfusion system, even in large doses (50 micrograms/min, or 500 micrograms/min).

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6454019     DOI: 10.1254/jjp.30.881

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  8 in total

1.  Nicorandil and cardiovascular performance in anaesthetized pigs with a concentric coronary artery stenosis.

Authors:  L M Sassen; L K Soei; T J Heere; L J van Woerkens; P R Saxena; P D Verdouw
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-12       Impact factor: 3.000

Review 2.  Management of vasospastic angina--role of nicorandil.

Authors:  J C Kaski
Journal:  Cardiovasc Drugs Ther       Date:  1995-03       Impact factor: 3.727

3.  In vitro protective effects of nicorandil on hypothermic injury to immature cardiac myocytes: comparison with nitroglycerin.

Authors:  H Orita; M Fukasawa; S Hirooka; K Fukui; M Kohi; M Washio
Journal:  Cardiovasc Drugs Ther       Date:  1994-02       Impact factor: 3.727

4.  A modified product inhibition model describes the nonlinear pharmacokinetics of nicorandil in rats.

Authors:  E L Bachert; Z W Li; L Zhao; S J Chung; H L Fung
Journal:  Pharm Res       Date:  1994-08       Impact factor: 4.200

5.  Pharmacokinetics of nicorandil in patients with normal and impaired renal function.

Authors:  M Molinaro; G Villa; M B Regazzi; A Salvadeo; S Segagni; R Rondanelli; E Sartirana
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 6.  Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris.

Authors:  J Frampton; M M Buckley; A Fitton
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

7.  Coronary effects of nicorandil in comparison with nitroglycerin in chronic conscious dogs.

Authors:  K Hashimoto; M Kinoshita; Y Ohbayashi
Journal:  Cardiovasc Drugs Ther       Date:  1991-02       Impact factor: 3.727

8.  Relationship between relaxation and cyclic GMP formation caused by nicorandil in canine mesenteric artery.

Authors:  M Endoh; N Taira
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-05       Impact factor: 3.000

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.